论文部分内容阅读
Objective: The effectiveness ofgemcitabine in treating refractory or relapse non-Hodgkin lymphoma was retrospectively analyzed.Methods: A total of 53 refractory or relapsed lymphoma patients who received second-line chemotherapy between January 2009and December 2012 were included.Among the patients, 38patients received chemotherapy that contained gemcitabine(gemcitabine group), and 15 patients received other second-line chemotherapy without gemcitabine (non-gemcitabine group).The efficacy and adverse effects of gemcitabine were studied bycomparing the two groups.Furthermore, the different effects of gemcitabine in treatin1g T-cell lymphoma versus B-cell lymphoma were also evaluated among the patients in the gemcitabine group.